Cargando…

Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells

Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and isolated from numerous hematological and solid malignancies. These stem-like tumor cells can persist following conventional cytoreductive therapies, such as chemotherapy and radiotherapy, thereby repopulating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luna, Jesus I., Grossenbacher, Steven K., Sturgill, Ian R., Ames, Erik, Judge, Sean J., Bouzid, Lyes A., Darrow, Morgan A., Murphy, William J., Canter, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356940/ https://www.ncbi.nlm.nih.gov/pubmed/30646520 http://dx.doi.org/10.3390/cancers11010085

Ejemplares similares

Bortezomib sensitizes human glioblastoma stem cells to adoptive natural killer cell cytotoxicity
por: Grossenbacher, Steven, et al.
Publicado: (2015)

Enhanced natural killer cell targeting of cancer stem cells using Cetuximab
por: Grossenbacher, Steven K, et al.
Publicado: (2014)

Natural killer cell immunotherapy to target stem-like tumor cells
por: Grossenbacher, Steven K., et al.
Publicado: (2016)

Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial
por: Canter, Robert J., et al.
Publicado: (2017)

Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target
por: Gingrich, Alicia A., et al.
Publicado: (2021)

Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer
por: Judge, Sean J., et al.
Publicado: (2020)

Intratumoral NKp46(+) natural killer cells are spatially distanced from T and MHC-I(+) cells with prognostic implications in soft tissue sarcoma
por: Cruz, Sylvia M., et al.
Publicado: (2023)

Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
por: Perry, Lauren M, et al.
Publicado: (2023)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence
por: Judge, Sean J., et al.
Publicado: (2020)

Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance
por: Razmara, Aryana M., et al.
Publicado: (2021)

Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia–telangiectasia
por: Judge, Sean James, et al.
Publicado: (2018)

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas
por: Judge, Sean J, et al.
Publicado: (2020)

A possible new pathway in natural killer cell activation also reveals the difficulty in determining human NK cell function in cancer
por: Canter, Robert J., et al.
Publicado: (2018)

Combination radioimmunotherapy with adoptive NK transfer targets cancer stem cells in canine models of bone and soft tissue sarcoma
por: Canter, Robert, et al.
Publicado: (2015)

Activation status dictates the function of unlicensed natural killer cells in mice and humans
por: Aguilar, Ethan G., et al.
Publicado: (2021)

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma
por: Canter, Robert J, et al.
Publicado: (2014)

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy
por: Gingrich, Alicia A., et al.
Publicado: (2019)

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
por: Chen, Chen, et al.
Publicado: (2017)

Transcriptome Analysis of Tumor-Infiltrating Lymphocytes Identifies NK Cell Gene Signatures Associated With Lymphocyte Infiltration and Survival in Soft Tissue Sarcomas
por: Judge, Sean J., et al.
Publicado: (2022)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
por: O’Connor-Byrne, N., et al.
Publicado: (2019)

Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
por: Lundqvist, Andreas, et al.
Publicado: (2011)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8(+)T cell antitumor function
por: Pellom, Samuel T., et al.
Publicado: (2016)

The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
por: Toualbi, Lyes, et al.
Publicado: (2021)

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
por: Suzuki, Erika, et al.
Publicado: (2011)

Augmentation of mouse natural killer activity and induction of interferon by tumor cells in vivo
Publicado: (1980)

Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
por: Chen, Ziqing, et al.
Publicado: (2019)

Bortezomib in Kidney Transplantation
por: Raghavan, Rajeev, et al.
Publicado: (2010)

Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
por: Monjazeb, Arta M, et al.
Publicado: (2013)

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival
por: Gras Navarro, Andrea, et al.
Publicado: (2019)

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma
por: Shanmugam, Muthu K., et al.
Publicado: (2018)

Natural Killer Cell Evasion Is Essential for Infection by Rhesus Cytomegalovirus
por: Sturgill, Elizabeth R., et al.
Publicado: (2016)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model
por: Yu, Ping, et al.
Publicado: (2014)

Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the “obesity paradox”
por: Vick, Logan V., et al.
Publicado: (2023)

ABT-737 synergizes with Bortezomib to kill melanoma cells
por: Reuland, Steven N., et al.
Publicado: (2011)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_55lnfm4e6v8uvsn8gbu8d788at